QRG Capital Management Inc. Sells 1,330 Shares of United Therapeutics Corporation $UTHR

QRG Capital Management Inc. lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 28.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,360 shares of the biotechnology company’s stock after selling 1,330 shares during the quarter. QRG Capital Management Inc.’s holdings in United Therapeutics were worth $1,992,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Wellington Management Group LLP boosted its holdings in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the period. Darwin Global Management Ltd. bought a new stake in shares of United Therapeutics during the third quarter worth $317,617,000. Norges Bank acquired a new stake in shares of United Therapeutics during the fourth quarter worth $293,418,000. Avoro Capital Advisors LLC raised its holdings in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC lifted its position in United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after acquiring an additional 341,383 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

UTHR traded up $8.67 on Tuesday, hitting $555.92. 77,205 shares of the company were exchanged, compared to its average volume of 494,011. The stock’s fifty day moving average is $557.83 and its 200-day moving average is $528.36. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The company has a market cap of $23.60 billion, a PE ratio of 20.51, a PEG ratio of 1.82 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.63 earnings per share. As a group, equities research analysts expect that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. HC Wainwright boosted their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Royal Bank Of Canada cut their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Cantor Fitzgerald upped their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Finally, Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $619.42.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,894,849.68. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 613,218 shares of company stock worth $345,644,756 in the last 90 days. 8.60% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.